This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Pulmonary Diseases  • Pneumonia  • Emergency Medicine  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 16 words of the full text and any section headings.

In Reply: I appreciate the clarification and information on modifications to the pneumonia antibiotic timing measure.

Mike Mitka
mike.mitka@jama-archives.org
Senior Staff Writer
Medical News & Perspectives
JAMA

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2007;298:1398.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTER

Pneumonia Treatment Standards in Emergency Departments
Jerod M. Loeb and Nancy K. Lawler
JAMA. 2007;298(12):1397-1398.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Flavonoid, Eriodictyol, Induces Long-term Protection in ARPE-19 Cells through Its Effects on Nrf2 Activation and Phase 2 Gene Expression
Johnson et al.
IOVS 2009;50:2398-2406.
ABSTRACT | FULL TEXT